- Home
- ALGS vs TOI Comparison
ALGS vs TOI Comparison
Compare ALGS & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- TOI
- Stock Information
- Founded
- ALGS 2018
- TOI 2007
- Country
- ALGS United States
- TOI United States
- Employees
- ALGS N/A
- TOI N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- TOI Medical/Nursing Services
- Sector
- ALGS Health Care
- TOI Health Care
- Exchange
- ALGS Nasdaq
- TOI Nasdaq
- Market Cap
- ALGS 23.5M
- TOI 20.1M
- IPO Year
- ALGS 2020
- TOI N/A
- Fundamental
- Price
- ALGS $19.17
- TOI $0.18
- Analyst Decision
- ALGS Strong Buy
- TOI Strong Buy
- Analyst Count
- ALGS 1
- TOI 1
- Target Price
- ALGS $75.00
- TOI $2.50
- AVG Volume (30 Days)
- ALGS 476.7K
- TOI 297.4K
- Earning Date
- ALGS 11-06-2024
- TOI 11-13-2024
- Dividend Yield
- ALGS N/A
- TOI N/A
- EPS Growth
- ALGS N/A
- TOI N/A
- EPS
- ALGS N/A
- TOI N/A
- Revenue
- ALGS $5,997,000.00
- TOI $378,933,000.00
- Revenue This Year
- ALGS N/A
- TOI $29.17
- Revenue Next Year
- ALGS N/A
- TOI $16.43
- P/E Ratio
- ALGS N/A
- TOI N/A
- Revenue Growth
- ALGS N/A
- TOI 22.29
- 52 Week Low
- ALGS $6.76
- TOI $0.18
- 52 Week High
- ALGS $30.00
- TOI $2.50
- Technical
- Relative Strength Index (RSI)
- ALGS 82.79
- TOI 24.09
- Support Level
- ALGS $15.66
- TOI $0.25
- Resistance Level
- ALGS $21.89
- TOI $0.30
- Average True Range (ATR)
- ALGS 2.25
- TOI 0.04
- MACD
- ALGS 1.24
- TOI -0.01
- Stochastic Oscillator
- ALGS 79.79
- TOI -0.06
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.